Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243833 | 0.93 | CAPN1 (0.69) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7242752 | 0.90 | CAPN1 (0.63) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7232776 | 0.90 | CAPN1 (0.58) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7242851 | 0.88 | CHIA (0.58) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7232336 | 0.87 | CAPN1 (0.58) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7232621 | 0.87 | CAPN1 (0.54) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7233164 | 0.86 | CAPN1 (0.62) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7235830 | 0.85 | CAPN1 (0.56) | CAPN1CTSSTSHRHSD17B10CHIA | |
| SCHEMBL7238735 | 0.82 | CAPN1 (0.53) | CAPN1CTSSTSHRHSD17B10 | |
| SCHEMBL7233171 | 0.82 | CAPN1 (0.57) | CAPN1CTSSTSHRHSD17B10CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562827-B1 | For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages | ABBOTT LABORATORIES | 2003-05-13 | — | — | US | disclosed |